Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This study seeks to determine the optimum dose frequency of 5-Azacytidin (5-AZA) infusions
into the fourth ventricle of the brain. The study's primary objective is to establish the
maximum tolerated dose for infusions of 5-Azacytidine into the fourth ventricle in patients
with recurrent ependymoma. The study's secondary objective is to assess the antitumor
activity of 5-Azacytidine infusions into the fourth ventricle based upon imaging studies and
cytology.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston